Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US, Europe submissions for Allergan's Botox in overactive bladder following positive data

This article was originally published in Scrip

Executive Summary

Allergan's Botox (onabotulinumtoxinA) met its primary endpoints of reducing daily urinary incontinence (bladder leakage) episodes compared to placebo (p<0.001) in two Phase III clinical trials. Announced as part of its 28 March R&D day for analysts and investors, the trials were in patients with idiopathic overactive bladder (OAB) who have an inadequate response to or are intolerant of an anticholinergic medication. The results could give Allergan another revenue source for its antiwrinkle product.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts